See also Factor Xa inhibitors, direct

General information

Apixaban is a follow-up compound with high oral systemic availability (50–85%) and a half-life of about 12 hours. Apixaban is cleared through renal (25%) and fecal routes and is given twice daily. It has been tested in the prevention and treatment of venous thromboembolism, for the prevention of stroke or systemic embolism in patients with atrial fibrillation, and for the management of acute coronary syndrome [ ].

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here